Therapeutic options for frontline management of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) are rapidly evolving. Are you up to date on the evidence? Credit available for this activity expires: 09/27/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001657?ecd=bdc_podcast_libsyn_mscpedu)
